Wickii Vigneswaran, MD, MBA, FACS
Dr. Wickii Vigneswaran is a thoracic surgeon and oncologist and a leader in robotic surgery for pleural mesothelioma and lung cancer. He is certified by the Royal College of Physicians and Surgeons of Canada in thoracic surgery; the Royal College of Surgeons of Great Britain and Ireland; a fellow of the College of Physicians and Surgeons of Canada; Royal College of Surgeons of Edinburgh; and the American College of Surgeons.[1]
Dr. Vigneswaran has advanced expertise in video-assisted thoracoscopic surgery, lung transplantation, mediastinal and chest wall tumors, and lung cancer diagnosis and surgical treatment.
Education and Career
Dr. Vigneswaran earned his medical degree at the University of Peradeniya in Sri Lanka. He completed several residencies in the United Kingdom, including rotations in Emergency Medicine at the Walsall General Hospital; in Anesthesiology at the Royal Victoria Infirmary; in General Surgery at the Freeman Hospital; and in Thoracic Surgery at the Royal Infirmary of Glasgow and Royal Infirmary of Edinburgh.[1]
After completing his residencies, Dr. Vigneswaran pursued fellowships in Thoracic Surgery at several medical institutions in both the United States and the United Kingdom, including the University of Colorado School of Medicine; the Royal Infirmary of Edinburgh; St. Mary’s Hospital in London; Harefield Hospital in England; and the Mayo Clinic School of Graduate Medical Education.[1]
Dr. Vigneswaran has had a storied career that took him from being an Assistant Professor of Surgery at the University of Illinois to an Associate Professor and Chief of Thoracic Surgery at Loyola University and Stritch School of Medicine. At Loyola, he rose to the position of Professor of Thoracic and Cardiovascular Surgery, Chief of Thoracic Surgery, and Director of Lung and Heart-Lung Transplant as well as Associate Director of Thoracic Oncology, then moved back to the University of Chicago as Professor of Surgery and Associate Chief of Cardiac and Thoracic Surgery. After a return to Loyola University Health System as Professor of Thoracic and Cardiovascular Surgery and Director of Thoracic Surgery, he accepted the role of Thoracic Surgeon at James A. Haley VA Hospital in Tampa, Florida, and Professor at the University of South Florida’s Morsani College of Medicine.[]
Professional Memberships and Activities
Dr. Vigneswaran is past president of the International College of Surgeons and a trustee for the Chest Foundation of the American College of Chest Physicians. He is a member of the Cardiothoracic Surgery Network, the European Association for Cardio-Thoracic Surgery, the General Thoracic Surgical Club, the International Society for Minimally Invasive Cardiothoracic Surgery, and The Society of Thoracic Surgeons.[1]
Research
Dr. Vigneswaran has dedicated much of his career to researching quality of life and outcomes following thoracic surgery, minimally invasive surgery, molecular and basic cancer research and transplantation, and reperfusion injury and organ preservation.
His most recent publications include:[2]
INTERCONNECTION BETWEEN THROMBO-INFLAMMATORY AND OXIDATIVE STRESS-RELATED BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER. Oct 2023. Srdjan Nikolovski, Fakiha Siddiqui, DEBRA HOPPENSTEADT[…], Wickii T Vigneswaran
PURPOSE: Lung cancer is one of the most common and the deadliest malignancy globally. Thromboembolic events have been associated with increased mortality and adverse outcomes. This study compared the levels of thrombo-inflammatory and oxidative stress biomarkers in patients with non-small cell lung cancer (NSCLC) to normal human population (NHP) and.. Summary video of Case 3—includes demonstrations of the methylene blue localization technique and the Gigli saw rib shearing technique. Sep 2023. Raymond A. Verm, Wickii T Vigneswaran, Andrew Lin[…], Zaid M Abdelsattar. Demographic and clinical information for institutional case series. Operative details and pathological findings for institutional case series. Comparison of institutional case series and NCDB series
Robotic chest wall resection for primary benign chest wall tumors and locally advanced lung cancer: an institutional case series and national report. Sep 2023. Raymond A. Verm, Wickii T Vigneswaran, Andrew Lin[…], Zaid M Abdelsattar. Background Limited data exists for robotic chest wall resection; we report institutional and national experience of robotic chest wall resection. Methods In this comparative retrospective case series we describe patients who underwent robotic chest wall resection at our institution and enrich this case series with data from the National Cancer Dat…
Bi-directional interaction and predictive potential of inflammatory and oxidative stress-related biomarkers in patients with non-small cell lung cancer. Jun 2023. Srdjan Nikolovski, Mark Jaradeh, Fakiha Siddiqui[…], Wickii T Vigneswaran. e15030 Background: Interplay between oxidative stress and inflammation play major role in the development and progression of various malignancies. As one of the most common and the deadliest malignancy, lung cancer has a prominent vicious cycle of oxidative stress and immune response. The aim of this study is to examine the inter-relationship betwe…
Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-Stage Lung Cancer. Dec 2022. Matthew Khouzam, Douglas E. Wood, Wickii T Vigneswaran[…], Zaid M. Abdelsattar. BACKGROUND In December 2013, the United States Preventative Services Task Force (USPSTF) recommended annual lung cancer screening for high-risk patients. The Centers for Medicare and Medicaid Services (CMS) later announced coverage in 2015. The impact of these federal decisions at the population-level is unknown. METHODS Using the Surveillance, Ep…
The Inter-Relationship between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Early-Stage Lung Cancer Patients. Nov 2022, Mark Jaradeh, Brett Curran, Kostantinos Poulikidis[…], Wickii T Vigneswaran. Pooled specificity and sensitivity values of biomarkers.
Malignant Pleural Mesothelioma: Current Understanding of the Immune Microenvironment and Treatments of a Rare Disease. Sep 2022. John Tedesco, Mark Jaradeh, Wickii T Vigneswaran. Malignant pleural mesothelioma is a rare disease with an annual incidence of around 3000 cases a year in the United States. Most cases are caused by asbestos exposure, with a latency period of up to 40 years. Pleural mesothelioma is an aggressive disease process with overall survival of roughly 6–12 months after the time of diagnosis…
